Key result
Vitamin K antagonist initiation in patients with thromboembolic disease is associated with a paradoxical increased risk of thrombosis.
Why the study?
Does initiation of Vitamin K Antagonists increase the risk of thrombosis in patients with thromboembolic disease?
Does initiation of Vitamin K Antagonists increase the risk of thrombosis in patients with thromboembolic disease?
The text highlights a paradoxical increased risk of thrombosis following the initiation of Vitamin K Antagonists in patients with thromboembolic disease.
Concurrent LMWH/VKA initiation at diagnosis remains standard; level 5 data leaves open individualized bridging optimization.
Vitamin k Antagosnist Oral Anticoagulants (VKA) are effective in the primary and secondary prevention of venous thromboembolism, in the prevention of systemic embolism and stroke in patients with prosthetic heart valves or atrial fibrillation. In patients with thromboembolic disease Low Molecular Weight Heparin (LMWH) and oral VKA are started at diagnosis.
No takes yet. Share an insight, caveat, or question.
A 2013 study studied this question. Vitamin K antagonist initiation in patients with thromboembolic disease is associated with a paradoxical increased risk of thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: